A Phase 3 interventional study of Placebo (for alirocumab) and Alirocumab in Hypercholesterolemia, sponsored by Sanofi. Completed at 32 sites in Japan. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-10-04.
Sponsored by Sanofi · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies testing alirocumab in Hypercholesterolemia — 1 open to participants now, 2 under way, none of them phase 3. alirocumab · Hypercholesterolemia.
Among the 43 studies testing alirocumab in Hypercholesterolemia, this one is the 17th largest by enrollment, is the only one that started in 2014, is one of 20 in phase 3, and was the 27th registered.
1,177 studies on the registry are indexed under Hypercholesterolemia; 95 are open to participants now.
Browse Hypercholesterolemia studies →1 of the 43 studies testing alirocumab in Hypercholesterolemia is open now, in 1 country. Recruiting first, the newest first:
University Medical Centre Ljubljana · Sites in Slovenia
Ages 18+
By country, each count listing its studies:
alirocumab: first FDA approval 2015 (PRALUENT), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →
Of the 55 Hypercholesterolemia studies recruiting now, 23 (42%) set no upper age limit and 20 (36%) stop at 75 or younger; 9 take children under 18; 11 take healthy volunteers.
This study: 20 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 216 is above the median of 110 across 976 interventional studies indexed under Hypercholesterolemia.
Median enrollment 107 across the 43 interventional studies. Of the 40 that completed or were terminated, 30 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 43 have an industry lead sponsor. The 6 most frequent:
Sanofi is the lead sponsor of 1,558 studies on the registry; 89 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 123 (60%) have results posted.
38 studies in Hypercholesterolemia by Sanofi: none open now, none under way, none of them phase 3. Of 38 finished, 22 (58%) have results posted.
Among the 38 studies in Hypercholesterolemia by Sanofi, this one is the 15th largest by enrollment, is the only one that started in 2014, is one of 22 in phase 3, and was the 26th registered.
Sanofi’s Hypercholesterolemia studies by the year they started, since 2007.
2 of the studies testing alirocumab in Hypercholesterolemia that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07477704Regeneron PharmaceuticalsA Study to See How Safe and Effective Alirocumab is When Given Weekly to Adult Participants Who Have Hypercholesterolemia | 2026-12-29 |
| NCT07581808University Medical Centre LjubljanaDual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies testing alirocumab in Hypercholesterolemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Sanofi’s 38 in Hypercholesterolemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Primary Objective:
To demonstrate the reduction of low-density lipoprotein cholesterol (LDL-C) by alirocumab as add-on therapy to stable daily statin therapy with or without other lipid modifying therapy in comparison with placebo after 24 weeks of treatment in heterozygous familial hypercholesterolemia (HeFH) or high cardiovascular risk participants with hypercholesterolemia.
Secondary Objectives:
Total duration per participant of approximately 63 weeks (14 months) (screening: 3 weeks, double-blind treatment period: 52 weeks, and follow-up period: 8 weeks).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with heterozygous familial hypercholesterolemia or non-familial hypercholesterolemia who were not adequately controlled with a stable daily dose of statin with or without other lipid modifying therapy, at stable dose prior to the screening visit (Week -3).
Exclusion criteria:
The above information is not intended to contain all considerations relevant to a participants' potential participation in a clinical trial.
Placebo (for alirocumab) every two weeks (Q2W) added to stable lipid-modifying therapy (LMT).
Drug: Placebo (for alirocumab) · Drug: Lipid-Modifying Therapy (LMT)
Alirocumab 75 mg Q2W added to stable LMT for 52 weeks. Alirocumab dose up-titrated to 150 mg from Week 12 when LDL-C levels above pre-specified threshold at Week 8 as defined in Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012 i.e. * ≥100 mg/dL (2.59 mmol/L) in heFH participants or in non-familial hypercholesterolemia (non-FH) participants who had a history of documented coronary heart disease (CHD) * ≥120 mg/dL (3.10 mmol/L) in non-FH participants who had a history of documented diseases or other risk factors as categorized in primary prevention category III
Drug: Alirocumab · Drug: Lipid-Modifying Therapy (LMT)
Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
Also known as: SAR236553, REGN727, Praluent
Statin (pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin) at stable dose with or without other LMT as clinically indicated.
Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis)
Adjusted least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) (on-treatment analysis).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From baseline to Week 24
Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).
Time frame: From Baseline to Week 24
Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo B at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Total-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percentage of Participants Reaching Calculated LDL-C Goal at Week 24 - ITT Analysis
Calculated LDL-C goal was defined as: * \<100 mg/dL (2.59 mmol/L) for heFH or non-FH participants who had a history of documented congestive heart disease (CHD), or * \<120 mg/dL (3.10 mmol/L) for non-FH participants who had a history of documented diseases (ischemic stroke, peripheral artery disease, chronic kidney disease or diabetes) or other risk factors as defined in JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012. Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in imputation model.
Time frame: Up to Week 24
Percentage of Participants Reaching Calculated LDL-C Goal at Week 24 - On-Treatment Analysis
Adjusted percentages at Week 24 were from multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).
Time frame: Up to Week 24
Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis
Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment were included in the imputation model.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis
Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo A1 at Week 24 - ITT Analysis
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Apo A1 at Week 12 - ITT Analysis
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 24
Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis
Adjusted LS means and standard errors at Week 52 from MMRM model including available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
Time frame: From Baseline to Week 52
Percent Change From Baseline in Calculated LDL-C at Week 52 - On-Treatment Analysis
Adjusted LS means and standard errors at Week 52 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
Time frame: From Baseline to Week 52
The study was conducted at 31 centers in Japan. A total of 319 participants were screened between March 2014 and July 2014, 103 of whom were screen failures. Screen failures were mainly due to exclusion criteria met.
| Milestone | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Started | 72 | 144 |
| Treated | 72 | 143 |
| Completed | 66 | 132 |
| Not completed | 6 | 12 |
| Withdrew: Adverse event | 4 | 7 |
| Withdrew: Poor compliance to protocol | 0 | 1 |
| Withdrew: Participant moved | 0 | 2 |
| Withdrew: Consent withdrawn by participant | 2 | 1 |
| Withdrew: Randomized but not treated | 0 | 1 |
Adjusted least-squares (LS) means and standard errors at Week 24 were obtained from a mixed-effect model with repeated measures (MMRM) to account for missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were used in the model (ITT analysis).
| percent change | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 24 - Intent-to-Treat (ITT Analysis) | 1.6 ± 1.8 | -62.5 ± 1.3 |
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection) (on-treatment analysis).
| percent change | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 24 - On-Treatment Analysis | 1.7 ± 1.7 | -63.7 ± 1.2 |
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12 - ITT Analysis | -2.7 ± 1.6 | -64.2 ± 1.1 |
Adjusted LS means and standard errors at Week 12 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).
| percent change | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 12 - On-treatment Analysis | -2.8 ± 1.5 | -64.8 ± 1.1 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Apolipoprotein (Apo) B at Week 24 - ITT Analysis | -1.6 ± 1.7 | -55.0 ± 1.2 |
Adjusted LS means and standard errors at Week 24 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).
| percent change | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Apo B at Week 24 - On-Treatment Analysis | -2.1 ± 1.7 | -55.9 ± 1.2 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Non-High Density Lipoprotein Cholesterol (Non-HDL-C) at Week 24 - ITT Analysis | 2.6 ± 1.6 | -54.9 ± 1.2 |
Adjusted LS means and standard errors at Week 24 from MMRM model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).
| percent change | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 24 - On-Treatment Analysis | 2.6 ± 1.6 | -56.0 ± 1.1 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Total Cholesterol (Total-C) at Week 24 - ITT Analysis | 2.0 ± 1.3 | -39.5 ± 0.9 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Apo B at Week 12 - ITT Analysis | -3.3 ± 1.5 | -54.6 ± 1.1 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Non-HDL-C at Week 12 - ITT Analysis | -1.7 ± 1.4 | -56.3 ± 1.0 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Total-C at Week 12 - ITT Analysis | -2.1 ± 1.1 | -41.1 ± 0.8 |
Calculated LDL-C goal was defined as: * \<100 mg/dL (2.59 mmol/L) for heFH or non-FH participants who had a history of documented congestive heart disease (CHD), or * \<120 mg/dL (3.10 mmol/L) for non-FH participants who had a history of documented diseases (ischemic stroke, peripheral artery disease, chronic kidney disease or diabetes) or other risk factors as defined in JAS Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2012. Adjusted percentages at Week 24 were obtained from multiple imputation approach model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment were included in imputation model.
| percentage of participants | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percentage of Participants Reaching Calculated LDL-C Goal at Week 24 - ITT Analysis | 10.2 | 96.7 |
Adjusted percentages at Week 24 were from multiple imputation approach model including available post-baseline on-treatment data from Week 4 to Week 24 (i.e. up to 21 days after last injection).
| percentage of participants | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percentage of Participants Reaching Calculated LDL-C Goal at Week 24 - On-Treatment Analysis | 10.6 | 97.9 |
Adjusted means and standard errors at Week 24 from a multiple imputation approach followed by robust regression model for handling of missing data. All available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment were included in the imputation model.
| percent change | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) at Week 24 - ITT Analysis | 2.5 ± 2.5 | -39.5 ± 1.8 |
Adjusted means and standard errors at Week 24 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides at Week 24 - ITT Analysis | 6.7 ± 3.7 | -15.3 ± 2.6 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in HDL-C at Week 24 - ITT Analysis | 2.1 ± 1.5 | 7.9 ± 1.1 |
Adjusted LS means and standard errors at Week 24 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Apo A1 at Week 24 - ITT Analysis | -2.6 ± 1.6 | 1.4 ± 1.1 |
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Lipoprotein (a) at Week 12 - ITT Analysis | -0.5 ± 2.4 | -41.9 ± 1.7 |
Adjusted means and standard errors at Week 12 from multiple imputation approach followed by robust regression model including all available post-baseline data from Week 4 to Week 24 regardless of status on-or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Fasting Triglycerides at Week 12 - ITT Analysis | 2.4 ± 3.7 | -13.1 ± 2.6 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in HDL-C at Week 12 - ITT Analysis | -1.8 ± 1.2 | 4.7 ± 0.8 |
Adjusted LS means and standard errors at Week 12 from MMRM model including all available post-baseline data from Week 4 to Week 24 regardless of status on- or off-treatment.
| percent change | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Apo A1 at Week 12 - ITT Analysis | -4.8 ± 1.1 | 1.5 ± 0.8 |
Adjusted LS means and standard errors at Week 52 from MMRM model including available post-baseline data from Week 4 to Week 52 regardless of status on- or off-treatment.
| Percent change | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 52 - ITT Analysis | -3.6 ± 1.9 | -62.5 ± 1.4 |
Adjusted LS means and standard errors at Week 52 were obtained from MMRM model including available post-baseline on-treatment data from Week 4 to Week 52 (i.e. up to 21 days after last injection).
| Percent change | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W |
|---|---|---|
| Percent Change From Baseline in Calculated LDL-C at Week 52 - On-Treatment Analysis | -3.4 ± 1.7 | -64.6 ± 1.2 |
Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (Week 60 post-treatment follow-up visit) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Q2W | — | 9/72 (12.5%) | 44/72 (61.1%) |
| Alirocumab 75 mg/ Up to 150 mg Q2W | — | 10/143 (7%) | 97/143 (67.8%) |
| Event | Placebo Q2W | Alirocumab 75 mg/ Up to 150 mg Q2W |
|---|---|---|
| Traumatic fractureInjury, poisoning and procedural complications | 2/72 | 1/143 |
| Pyelonephritis acuteInfections and infestations | 1/72 | 1/143 |
| Pancreatic carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/72 | 0/143 |
| Myocardial infarctionCardiac disorders | 1/72 | 1/143 |
| Coronary artery stenosisCardiac disorders | 1/72 | 0/143 |
| Intestinal obstructionGastrointestinal disorders | 1/72 | 0/143 |
| SpondylolisthesisMusculoskeletal and connective tissue disorders | 1/72 | 0/143 |
| Nephrotic syndromeRenal and urinary disorders | 1/72 | 0/143 |
| ProstatitisReproductive system and breast disorders | 1/72 | 0/143 |
| Medical device discomfortGeneral disorders | 1/72 | 0/143 |
| Event | Placebo Q2W | Alirocumab 75 mg/ Up to 150 mg Q2W |
|---|---|---|
| NasopharyngitisInfections and infestations | 26/72 | 65/143 |
| Back painMusculoskeletal and connective tissue disorders | 4/72 | 18/143 |
| Injection site reactionGeneral disorders | 3/72 | 18/143 |
| Diabetes mellitusMetabolism and nutrition disorders | 4/72 | 12/143 |
| InfluenzaInfections and infestations | 6/72 | 1/143 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 6/72 | 4/143 |
| FallInjury, poisoning and procedural complications | 5/72 | 11/143 |
| Seasonal allergyImmune system disorders | 5/72 | 1/143 |
| HypertensionVascular disorders | 5/72 | 9/143 |
| PharyngitisInfections and infestations | 4/72 | 9/143 |
| Age, Continuous(years) | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W | Total |
|---|---|---|---|
| Mean | 61.8 ± 9.0 | 60.3 ± 9.7 | 60.8 ± 9.5 |
| Sex: Female, Male(Participants) | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W | Total |
|---|---|---|---|
| Female | 25 | 60 | 85 |
| Male | 47 | 84 | 131 |
| Calculated LDL-C in mg/dL(mg/dL) | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W | Total |
|---|---|---|---|
| Mean | 141.6 ± 26.7 | 140.9 ± 26.8 | 141.2 ± 26.7 |
| Calculated LDL-C in mmol/L(mmol/L) | Placebo Q2W | Alirocumab 75 mg/Up to 150 mg Q2W | Total |
|---|---|---|---|
| Mean | 3.668 ± 0.691 | 3.650 ± 0.693 | 3.656 ± 0.691 |
The record gives a start of Mar 2014, a primary completion of Jan 2015 and a completion of Sep 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2016, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Alirocumab